Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Allergan enters billion-dollar deal for MedImmune's Crohn's/colitis candidate; AZ regains all rights

Executive Summary

AstraZeneca's MedImmune LLC granted Allergan PLC exclusive global rights to develop and sell its MEDI2070, an interleukin-23 monoclonal antibody in Phase IIb for Crohn's disease and entering Phase II ulcerative colitis and related disorders.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies